| Product Name | Terlipressin |
| Synonyms | Glypressin, Remestyp, Terlivaz, TGLVP, triglycyl lysine vasopressin, [N-α-triglycyl-8-lysine]-vasopressin |
| CAS Number | 14636-12-5; diacetate salt 1884420-36-3 |
| Sequence (3-Letter) | H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH₂ (cyclic Cys4–Cys9 disulfide) |
| Sequence (1-Letter) | GGGCYFQNCPKG-NH₂ (disulfide Cys4–Cys9) |
| Molecular Formula | C₅₂H₇₄N₁₆O₁₅S₂ |
| Molecular Weight | 1227.37 |
| Category | Drug Peptide – Vasopressin Analog (Prodrug) |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white powder |
| Counter Ion | Acetate (TFA-free available; salt form per specification) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Soluble in water |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research quantities to scale-up batches) |
| QC Documentation | COA, HPLC, MS identity (additional API/regulatory documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
Terlipressin is a synthetic 12-residue peptide and a long-acting analog of the hormone vasopressin (CAS 14636-12-5). Its sequence is H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2, closed by a disulfide bridge, and it is built as a prodrug, with three glycine residues added to the N-terminus of lysine vasopressin. It is known as a medicine under brand names such as Glypressin. We supply it as a white powder for research and pharmaceutical development.
Terlipressin is itself largely inactive. After it enters the body, enzymes slowly trim off the three N-terminal glycine residues to release the active lysine vasopressin. This makes terlipressin a slow-release reservoir, so its vasoconstricting action lasts for hours rather than the minutes typical of vasopressin. It acts mainly as a vasopressin V1 receptor agonist.
Clinically, terlipressin is used as a vasoactive drug, for example in acute bleeding from oesophageal varices, in hepatorenal syndrome, and in certain forms of shock that do not respond to standard treatment. This is background information only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply Terlipressin with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation. Additional documentation for API and regulatory work is available on request, and salt form and purity can be set to your specification.
Yes. We manufacture Terlipressin in-house and supply from research quantities up to scale-up batches. Contact us with your required purity, salt form, and quantity for a quote.
Terlipressin is a synthetic, long-acting analog of the hormone vasopressin, used as a vasoactive drug. It is built as a prodrug of lysine vasopressin and is known as a medicine under brand names such as Glypressin and Terlivaz. We supply it as a raw material for research and pharmaceutical development.
Terlipressin is a twelve-residue peptide with the sequence H-Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2, closed by a disulfide bridge between the two cysteine residues. Structurally it is lysine vasopressin with three extra glycine residues added at the N-terminus, which turn it into a prodrug. Its CAS number is 14636-12-5 (diacetate salt 1884420-36-3), its molecular formula is C52H74N16O15S2, and its molecular weight is about 1227.
On its own, terlipressin is largely inactive. Once in the body, aminopeptidase enzymes slowly remove the three N-terminal glycine residues and release the active lysine vasopressin. In effect terlipressin acts as a reservoir that releases the active peptide at a steady rate, so its vasoconstricting effect lasts for hours rather than the minutes seen with vasopressin itself. It acts mainly as an agonist at vasopressin V1 receptors, which constrict blood vessels.
Terlipressin is used clinically as a vasoactive drug, for example in acute bleeding from oesophageal varices, in hepatorenal syndrome, and in certain forms of shock that do not respond to standard treatment. This information is provided as scientific and reference background only. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use is subject to applicable regulatory approval.
We supply Terlipressin with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with further documentation available to support active pharmaceutical ingredient and regulatory work. Purity, salt form, and counter-ion can be set to your specification for use as a reference standard or in process development.
We manufacture Terlipressin by solid-phase synthesis, including the disulfide ring closure and the N-terminal triglycyl extension, and supply it from research quantities through to scale-up batches. For related capabilities, see drug peptides, custom peptide synthesis, peptide modification, and cyclic peptides. Material is supplied for research and pharmaceutical manufacturing use only.
